Market revenue in 2023 | USD 868.3 million |
Market revenue in 2030 | USD 1,202.2 million |
Growth rate | 4.8% (CAGR from 2023 to 2030) |
Largest segment | Crohn's disease |
Fastest growing segment | Ulcerative Colitis |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Crohn's Disease, Ulcerative Colitis |
Key market players worldwide | AbbVie Inc, Takeda Pharmaceutical Co Ltd, Pfizer Inc, Biogen Inc, Novartis AG ADR, Eli Lilly and Co, UCB SA, Merck & Co Inc, Johnson & Johnson, Celltrion Healthcare |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to inflammatory bowel disease treatment market will help companies and investors design strategic landscapes.
Crohn's disease was the largest segment with a revenue share of 60.18% in 2023. Horizon Databook has segmented the Germany inflammatory bowel disease treatment market based on crohn's disease, ulcerative colitis covering the revenue growth of each sub-segment from 2018 to 2030.
Germany held the largest share in Europe inflammatory bowel disease treatment market owing to the rising prevalence of ulcerative colitis and Crohn’s disease. For instance, in 2019, nearly 350,000 people were diagnosed with IBD in Germany.
Moreover, HaFCED, a research institute in Germany, implemented a national IBD registry to collect data on IBD patients about usefulness of treatment, which helps improve the treatment rate in the country.
Moreover, the collaborations between companies to innovate treatment approaches for IBD are fueling the market. For instance, in June 2022, Boehringer Ingelheim collaborated with BiomX to identify biomarkers for the disease using the XMarker discovery platform of BiomX.
Horizon Databook provides a detailed overview of country-level data and insights on the Germany inflammatory bowel disease treatment market , including forecasts for subscribers. This country databook contains high-level insights into Germany inflammatory bowel disease treatment market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account